XVIII International AIDS Conference

Role of Dendritic Cells in HIV Infection TUPDA1

Oral Poster Discussion Back
Location: MR 1
Schedule: 13:00 - 14:00, 20.07.2010
Code: TUPDA1
Chair: Heribert Stoiber, Austria

Presentations in this session:

Unique functional properties of dendritic cells in HIV-1 elite controllers
Presented by Mathias Lichterfeld, United States
J. Huang1, P. Burke1, F. Peyrera1, B. Walker1, L. Borges2, M. Lichterfeld3, X.G. Yu1
1Ragon Institute of Massachusetts General Hospital, MIT and Harvard, Charlestown, United States, 2Amgen Inc., Seattle, United States, 3Infectious Disease Division, Massachusetts General Hospital, Boston, United States

Neutralizing antibodies inhibit HIV-1 transfer
Presented by Vincent Holl, France
V. Holl, M. Peressin, A. Proust, S. Schmidt, T. Decoville, G. Laumond, C. Moog
UMR_S UdS/INSERM U748, Strasbourg, France

BIT225 reduces the intracellular HIV-1 burden within monocyte derived dendritic cells resulting in reduced transfer of virus to more permissive CD4+ T-cells
Presented by John Wilkinson, Australia
J. Wilkinson1, G. Ewart2, C. Luscombe2, M. Miller2
1Biotron Limited, St Vincent's Centre for Applied Medical Research, Sydney, Australia, 2Biotron Limited, Sydney, Australia

Cytotoxic mTRAIL+IFN-a+pDCHIV are generated following their cross-talk with NK cells - consequences on the control of viral replication
Presented by Marlene Bras, France
M. Bras, H. Saïdi, P. Formaglio, M.-T. Melki, M.-L. Gougeon
Pasteur Institute, Infection and Epidemiology, Paris, France

Co-adsorption of TLR3 ligand and HIV-1 antigens increase potency of biodegradable vaccine vehicles
Presented by Vincent Pavot, France
V. Pavot1, C. Weber2, C. Primard2, E. Luciani2, F. Gaudin2, S. Munier2, A. Borel2, C. Terrat2, A. Calamel2, T. Delair2, B. Verrier2
1IBCP UMR5086 - CNRS/Université Lyon1, Bernard Verrier Group, Lyon, France, 2UCBL, Lyon, France

Rapporteur report

Track A report by Rienk JEENINGA


This session was dedicated to the role of the different types of dendritic cells (DC) in HIV-1 infection. M. Lichterfeld (USA) discussed results showing that the so-called HIV-1 Elite Controllers (who spontaneously maintain viremia levels below limit of detection) have myeloid, but not plasmacytoid, dendritic cells (mDC and pDC, respectively) with a unique combination of increased antigen presenting and decreased cytokine-secretion properties. This functional profile is mediated and maintained by upregulation of the immunomodulatory receptors ILT2 and ILT5. This puts these receptors forward as potential targets to obtain viral control.

V. Holl (France) was replaced by A. Lederle who presented that neutralizing, but not non-neutralizing, antibodies (Ab) inhibit HIV-1 transmission from Langerhans’cells (i.e. immature DC of the skin) and interstitial dendritic cells to primary CD4+ T lymphocytes.

J.Wilkinson (Australia) demonstrated that a single administration of BIT225, a novel small molecule in drug development, reduced HIV-1 replication in monocyte-derived DC (MDDC). The short term transfer from MDCC exposing virions on their cell surface to T cells (trans modality) was not affected, but the cis transfer from productively infected MDCC to cells was inhibited by ca. 90%.

V.Pavot (France) demonstrated that co-adsorption of Poly(I:C) and HIV-1 CA-p24 antigen onto various biodegradable nanoparticles can be used to increase the anti-p24 Gag Ab (IgG) titer in sera but not at the mucosal surface.

The presentation of M. Bras (France) was canceled.


    The organizers reserve the right to amend the programme.

Contact Us | Site map © 2010 International AIDS Society